SynBiotic Future Growth

Future criteria checks 5/6

SynBiotic is forecast to grow earnings and revenue by 107% and 39.7% per annum respectively. EPS is expected to grow by 107.3% per annum. Return on equity is forecast to be 7.7% in 3 years.

Key information

107.0%

Earnings growth rate

107.3%

EPS growth rate

Pharmaceuticals earnings growth21.5%
Revenue growth rate39.7%
Future return on equity7.7%
Analyst coverage

Low

Last updated17 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DUSE:SBX - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026342333
12/31/2025260123
12/31/202416-2-3-33
12/31/20234-11-3-3N/A
12/31/20228-24-7-7N/A
12/31/20219-13-6-5N/A
12/31/20205-1-3-1N/A
12/31/2019N/A000N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SBX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: SBX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SBX is expected to become profitable in the next 3 years.

Revenue vs Market: SBX's revenue (39.7% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: SBX's revenue (39.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SBX's Return on Equity is forecast to be low in 3 years time (7.7%).


Discover growth companies